ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement

June 26, 1987

House Bill Gives NCI $48 Mil. Less Than Clinton Requested

July 8, 1994

High-Dose Chemo Doesn’t Improve Survival In Small Cell Lung Cancer

April 25, 2008

Women’s Health Trial RFPs Issued; Three Clinical Centers Sought

April 12, 1991

Patient Advocacy: NBCC Urges Funding For Treatment Of Women Screened In CDC Program

July 17, 1998

Concepts Approved for Primary Care, Worker Health, Black Interventions

May 17, 1985